Page 6 - Celcuity Inc News Today

Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib ...

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results ...

08.05.2023 - MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first ...

Gagnon Securities LLC decreased its holdings in Celcuity Inc. (NASDAQ:CELC – Get Rating) by 33.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,655 shares of the company’s stock after selling 26,998 shares during the period. Gagnon Securities LLC owned 0.35% […]

Celcuity (NASDAQ:CELC – Get Rating) and Aclarion (NASDAQ:ACON – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Earnings and Valuation This table compares Celcuity and Aclarion’s revenue, earnings […]

The multicancer early detection platform was developed based on methylation of cell-free DNA

Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib ...

Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference ...